



Indraprastha Medical Corporation Limited

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)

Corporate Identity Number : L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail : asinghal@apollohospitals.com Website : apollohospdelhi.com



Accredited by
Joint Commission International

A. K. SINGHAL

Vice President
Cum Company Secretary

Ref: IMCL/CS/BM/2019

26th July, 2019

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Sub.: Unaudited Financial Results for the quarter ended 30th June, 2019

Dear Sir,

Enclosed please find a copy of the Unaudited Financial Results for the quarter ended 30th June, 2019, along with a copy of the Limited Review Report by the Auditors.

The Board meeting started at 3:00 pm and ended at 5.00 p.m.

This is for your information and record.

Thanking You,

Sincerely Yours,

A.K.SINGHAL

Encl. as above

Statement of Unaudited Financial Results for the Quarter ended 30th June, 2019

Amount (Rs. in million)

S. No.	Particulars	Quarter ended			Year ended	
		30.06.2019 (Unaudited)	31.03.2019 (Audited)	30.06.2018 (Unaudited)	31.03.2019 (Audited)	
1	Revenue from operations	2036.93	2004.23	1893.79	7881.72	
2	Other Income	2.98	2.25	0.77	4.67	
3	Total income	2039.91	2006.48	1894.56	7886.39	
4	Expenses					
	a) Cost of material consumed	375.91	371.57	357.28	1449.62	
	b) Employee benefits expense	499.52	509.09	477.06	2002.05	
	c) Professional charges to doctors	508.80	488.17	488.16	1975.55	
	d) Finance cost	17.01	15.32	17.84	68.71	
	e) Depreciation and amortisation expense	80.65	71.78	75.45	297.54	
	f) Other expenses	426.00	440.56	376.20	1646.71	
	Total expenses	1907.89	1896.49	1791.99	7440.18	
5	Profit before exceptional items and tax	132.02	109.99	102.57	446.21	
6	Exceptional items	-	-	-	-	
7	Profit before tax (PBT)	132.02	109.99	102.57	446.21	
8	Tax expense					
	Current tax	59.40	42.04	47.98	185.28	
	Deferred tax	(12.63)	(3.40)	(10.27)	(23.20)	
9	Profit for the period after tax (PAT)	85.25	71.35	64.86	284.13	
10	Other comprehensive income					
	a. (i) Items that will not be reclassified to profit or loss	(5.79)	4.41	3.60	(1.72)	
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	2.02	(1.54)	(1.26)	0.60	
	Total other comprehensive income, Net of tax expenses	(3.77)	2.87	2.34	(1.12)	
11	Total comprehensive income for the period	81.48	74.22	67.20	283.01	
12	Paid-up equity share capital (Face value Rs. 10/- each)	916.73	916.73	916.73	916.73	
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year				1523.63	
14	Earnings per share Basic and Diluted (Rs.)	0.93	0.78	0.71	3.10	

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 26th July, 2019.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Statutory Auditors have carried out a limited review of the financial results for the quarter ending 30th June, 2019.
- The company has adopted Ind AS 116 'Leases' effective 1st April, 2019. This has an impact in the financial results of current period as an increase of Rs. 6.10 million in depreciation for the right-to-use assets, Rs. 2.61 million in finance costs on lease liability and a decrease in lease rent cost of Rs. 7.08 million.
- Previous year/period figures have been regrouped / rearranged wherever necessary. The figures for the quarter ended 31st March, 2019 are the balancing figures between audited figures in respect to the full financial year upto 31st March, 2019 and the unaudited published year to date figures upto 31st December, 2018, being the date of the end of the third quarter of the financial year which was subject to limited review.

Place : New Delhi
Date : 26th July, 2019




Dr. Prathap C. Reddy
(Vice - Chairman)

Limited Review Report on Unaudited Standalone Quarterly Results

To the Board of Directors of Indraprastha Medical Corporation Limited

1. We have reviewed the accompanying statement of unaudited financial results of Indraprastha Medical Corporation Limited ("the Company") for the quarter ended June 30, 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder; as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S.N. Dhawan & Co LLP**

Chartered Accountants

Firm Registration No.: 000050N/N500045



Rajceev K Saxena

Partner

Membership No.: 077974

UDIN: 19077974AAAAAW4661

New Delhi July 26, 2019

